INSL5 ELISA kit
- Known as:
- INSL5 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-INSL5-Hu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- INSL5 ELISA kit
Related genes to: INSL5 ELISA kit
- Gene:
- INSL5 NIH gene
- Name:
- insulin like 5
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 1p31.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-01-08
- Date modifiied:
- 2015-11-23
Related products to: INSL5 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: INSL5 ELISA kit
- Left-sided colon-cancer (LCC) and right-sided colon cancer (RCC) harbor different clinical entities and different therapy protocols. Our study aimed to demonstrate genomic expression differences and clarify the clinical differences between LCC and RCC by using in-silico methods. - Source: PubMed
Publication date: 2026/07/10
Solak Hatice CilemMert NazliLeblebici AsimIsik ZerrinEllidokuz Ender BeratBasbinar Yasemin - Insulin-like peptide 5 (INSL5) is a member of the relaxin/insulin peptide family, predominantly produced by enteroendocrine L cells in the distal gut. Although initially characterised based on its structural similarity to insulin and relaxin peptides, INSL5 is now increasingly recognised as an important regulator of gastrointestinal physiology. Its endogenous receptor, relaxin family peptide receptor 4 (RXFP4), is primarily expressed in the gastrointestinal tract and signals mainly through G proteins. Recent studies have provided compelling evidence that the INSL5-RXFP4 signalling axis is an important regulator of colonic motility. In this review, we summarise current knowledge of the structure-function relationships of INSL5 and RXFP4, advances in the design of INSL5 analogues, and the signalling mechanisms underlying receptor activation. We also discuss the physiological and pharmacological evidence supporting a role for INSL5-RXFP4 signalling in colonic motility and highlight opportunities for the development of chemical probes and therapeutic leads targeting this system for the treatment of chronic constipation. - Source: PubMed
Publication date: 2026/05/25
Wu HongkangWang HuahaoRiches IsabelleMaslov IvanKalaba PredragHan Myat NoePustovit RuslanFurness John BBathgate Ross A DHossain Mohammed Akhter - Immune dysregulation is increasingly recognized as an important contributor to the pathophysiology of irritable bowel syndrome (IBS). This study aimed to identify immune-related core genes in IBS and predict potential regulatory traditional Chinese medicines (TCMs). Two IBS-related Gene Expression Omnibus datasets were integrated and analyzed to identify differentially expressed genes (DEGs). Functional enrichment, immune cell infiltration profiling, and intersection with ImmPort immune-related genes were performed. Core genes were selected through 3 machine-learning algorithms, and potential TCMs were predicted using the Coremine Medical database. A total of 95 DEGs were identified, including 56 upregulated and 39 downregulated genes. Enrichment analyses indicated involvement in muscle system processes, membrane-associated structures, and peptidase inhibitor activity, with significant enrichment in the neuroactive ligand-receptor interaction pathway. Immune infiltration analysis showed increased M2 macrophages, resting natural killer cells, resting dendritic cells, and activated mast cells in IBS samples. Seven immune-related DEGs were obtained, among which LEFTY1, SLPI, and INSL5 were consistently recognized as core genes across all machine-learning approaches. These genes exhibited distinct immune regulatory relevance. Five TCMs: Drynaria fortunei, Crataegus pinnatifida, Houttuynia cordata, Poria cocos, and Bubalus bubalis horn were predicted as potential therapeutic agents targeting the core genes. LEFTY1, SLPI, and INSL5 represent key immune-related genes in IBS and may contribute to its immune regulatory mechanisms. The predicted TCMs provide potential candidates for further validation in IBS management. - Source: PubMed
Bai WeiQian ZixingYang YangHuang GuodongRao XianjunLi HaoZhou TingtingWei Wei - INTRODUCTION: Following the identification of the incretin effect, the role of the enterohormones in regulating food intake and energy balance was recognized, ushering in a new era in the pharmacotherapy of metabolic diseases. A constellation of hormones is released from the gastrointestinal tract, some of them with biological functions still not completely defined. The insulin-like peptide 5 (INSL5) is a recently discovered enterohormone with basic studies proposing a role in the gut-brain axis and hunger regulation, although evidence in humans remains limited. It is primarily produced in the distal colon, but growing reports suggest that its secretion may also be regulated to a proximal level. METHODS/RESULTS: We tested this hypothesis through hormone determination during an oral glucose tolerance test in a cohort of patients with severe obesity, observing an early decrease in plasma levels that overlapped with changes in blood glucose and insulin, supporting the idea that INSL5 could also represent a glucose/nutrient-responsive appetite-regulating hormone involved in food seeking. CONCLUSIONS: Far from establishing a direct role for gastric-jejunal mucosa or a gastric-colonic cross-talk after food ingestion, our results may incentivize future studies to confirm and validate these findings, and to explore INSL5 as a potential adjunctive target for obesity treatment. - Source: PubMed
Publication date: 2026/01/05
Di Vincenzo AngeloGranzotto MarnieMoreni LauraTrevellin ElisabettaCapone FedericoRossato Marco - - Source: PubMed
Publication date: 2026/01/08
Donowitz MarkSingh Varsha